Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Why Avenacy’s 27th injectable launch could matter more than its modest market size suggests
Injectable safety is becoming a workflow battle. Avenacy’s tranexamic acid launch tests demand for ready-to-use hospital formats.
Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a […]
Can Bristol Myers Squibb and Pfizer protect Eliquis growth as drug pricing pressure rises?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Can TCR bispecifics unlock prostate cancer immunotherapy? Why Pfizer is backing Flagship and Repertoire
Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and […]
Can anti-TFPI drugs like HYMPAVZI reshape the standard of care in inhibitor-positive hemophilia?
Pfizer Inc. has moved a step closer to reshaping the treatment paradigm for one of hemophilia’s most challenging patient subgroups. The company’s investigational therapy HYMPAVZI (marstacimab) demonstrated a 93 percent reduction in bleeding episodes in patients with hemophilia A or B who have developed inhibitors, according to data presented at the 67th American Society of […]
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.